Trial Summary
What is the purpose of this trial?To assess INCB05643 + ruxolitinib JAKi-naive patients with myelofibrosis
Eligibility Criteria
This trial is for patients who have primary myelofibrosis or myelofibrosis and haven't been treated with JAK inhibitors before. Specific inclusion and exclusion criteria details are not provided, but typically these would outline the health status required to participate.Inclusion Criteria
I am 18 years old or older.
Agree to use highly effective contraceptive methods
Written informed consent required
+5 more
Exclusion Criteria
I have had my spleen removed.
I have been treated with a JAK inhibitor like ruxolitinib.
I do not have an active or chronic infection with TB, HIV, Hepatitis B, or Hepatitis C.
+13 more
Participant Groups
The study is testing a combination of two drugs: INCB57643, which is a BET inhibitor, and Ruxolitinib. The goal is to see how effective this combo is for patients who have never taken JAK inhibitors.
1Treatment groups
Experimental Treatment
Group I: INCB+ RExperimental Treatment2 Interventions
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
The University of Texas MD Anderson Cancer CenterHouston, TX
Loading ...
Who Is Running the Clinical Trial?
M.D. Anderson Cancer CenterLead Sponsor